Clinical Trial Update: Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

View source ↗

Summary

A validation study of RA-INF-Dx, a multigene molecular test intended to predict non-response to infliximab in rheumatoid arthritis, has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Remicade (infliximab)

Snippet

Sponsor: TcLand Expression S.A. | Conditions: Rheumatoid Arthritis | Status: TERMINATED